CDXS News Alert Codexis Inc (CDXS) 2.45 12/25/2014 01:13:30

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Codexis Inc (CDXS) 2.45 $CDXS

Codexis Uses Its CodeEvolver(R) Protein Engineering Platform Technology to Develop an Enzyme Therapeutic Candidate for the Potential Treatment of Phenylketonuria (PKU) via Oral Administration
GlobeNewswire - Wed Dec 03, 5:38PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that it has developed a novel enzyme therapeutic product candidate for the potential treatment of phenylketonuria (PKU) via oral administration. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. As a result, phenylalanine accumulates in high levels in the brain causing serious neurological problems, including intellectual disability, seizures and cognitive and behavioral problems. Phenylalanine is found in many foods, including meat, dairy products, fish, poultry and many fruits and vegetables.
CDXS: 2.45 (-0.03)

Global Synthetic Biology Market 2013-2020 - Opportunities and Forecasts for the $38 Billion Market
M2 - Thu Nov 27, 6:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/g34xgv/global_synthetic) has announced the addition of the "Global Synthetic Biology Market (Products, Technologies, Applications and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The global synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020) Key factors fueling the growth of this market include assistance from government and private organizations, rising number of entities conducting research and declining cost of DNA sequencing and synthesizing. Bio-safety & bio-security and ethical issues are key restraining factors of the market. The fact that synthetic biology can be misused has raised concerns all around the world. However, as far as the market dynamics are considered, the bottom line is that the overall impact of these factors would be highly positive. Global synthetic biology market is segmented based on product, technology, application, and geography. Synthetic biology product market is further segmented into enabling products, enabled products and core products. Enabling product is the fastest growing segment in the product market due to ongoing researches that may bring-innovative ideas for application of synthetic biology in new fields. Thus, the need for enabling products, during R&D activities and in the development of enabled products, would rise. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Synthetic Biology Market By Product Chapter 5 Global Synthetic Biology Market By Technologies Chapter 6 Global Synthetic Biology Market By Application Chapter 7 Synthetic Biology Market By Geography Chapter 8 Company Profiles - Algenol Biofuels - BASF - BioAmber - BioSearch Technologies - Butamax Advanced Biofuels - Codexis Inc. - Dupont - GEN9 Inc. - Gensript Corporation - Origene Technologies - Synthetic Genomics For more information visit http://www.researchandmarkets.com/research/g3..._synthetic
CDXS: 2.45 (-0.03)

Codexis to Present at the LD Micro Main Event VII Conference on December 4
GlobeNewswire - Tue Nov 25, 7:07AM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will provide a corporate update at the LD Micro Main Event VII Conference, being held December 2-4, 2014 at The Luxe Hotel in Los Angeles, California.
CDXS: 2.45 (-0.03)

Insider Trading Alert - ITG, CDXS And ARQL Traded By Insiders
at The Street - Fri Nov 21, 1:45PM CST
Stocks with insider trader activity include ITG, CDXS and ARQL
ITG: 20.72 (-0.40), ARQL: 1.15 (+0.01), CDXS: 2.45 (-0.03)

Codexis' (CDXS) CEO John Nicols on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:50PM CST

CDXS: 2.45 (-0.03)

Codexis misses by $0.06, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:09PM CST

CDXS: 2.45 (-0.03)

Codexis Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2014
GlobeNewswire - Tue Nov 04, 3:03PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced financial results for the third quarter and nine months ended September 30, 2014.
CDXS: 2.45 (-0.03)

Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST

AMRS: 2.16 (-0.02), ITRI: 42.63 (+0.21), AWAY: 28.87 (+0.05), OKE: 50.71 (+0.33), HR: 27.54 (-0.02), NYMT: 7.71 (-0.06), OCLR: 1.87 (+0.02), ENPH: 14.38 (-0.02), ADEP: 8.35 (-0.16), CBSO: 27.51 (+0.58), NSTG: 13.93 (+0.02), MITT: 18.58 (-0.12), CRTO: 40.82 (unch), FOXA: 38.71 (-0.03), OKS: 41.05 (-0.04), JMBA: 14.53 (+0.14), IVR: 15.52 (-0.62), CSU: 25.08 (+0.10), MYGN: 36.50 (+0.28), JIVE: 6.08 (unch), GAS: 54.01 (+1.29), COUP: 17.44 (+0.69), NRP: 9.98 (+0.23), MOSY: 1.60 (+0.04), COHR: 62.43 (+0.22), DOX: 47.53 (+0.03), CKEC: 26.09 (+0.10), OAS: 16.66 (-1.05), PAYC: 26.49 (-0.88), PCYC: 121.84 (+1.15), AXLL: 41.52 (+0.11), NP: 59.82 (+0.19), BIRT: 6.60 (+0.02), ATVI: 20.35 (+0.12), EXAM: 41.16 (+0.96), P: 18.02 (-0.31), JAZZ: 165.33 (+1.83), PBPB: 12.11 (+0.08), EXEL: 1.29 (-0.01), CERS: 6.49 (+0.29), DVN: 60.21 (-1.26), FEYE: 32.38 (-1.11), CHUY: 19.28 (-0.19), FRGI: 56.97 (+0.47), GHDX: 32.44 (+1.32), PACD: 4.75 (-0.18), BIO: 120.32 (-0.04), BIOL: 2.63 (-0.07), JKHY: 63.50 (-0.07), KAR: 35.01 (-0.17), CDXS: 2.45 (-0.03), MPO: 1.63 (-0.05), FANG: 60.18 (-1.51), CORT: 2.94 (+0.06), CALD: 15.88 (+0.08)

Codexis Appoints Pam P. Cheng, Merck Global Executive, to Board of Directors
GlobeNewswire - Mon Nov 03, 3:01PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Pam Cheng to its board of directors. Ms. Cheng is a 17-year veteran of Merck & Co. and is currently serving as President of MSD China, where she has direct responsibility for $1.3 billion in sales and approximately 4,000 employees, covering a wide functional scope which includes commercial, R&D, manufacturing and various business support organizations.
MRK: 57.46 (+0.25), CDXS: 2.45 (-0.03)

Industrial Enzymes: Carbohydrases, Proteases, Lipases & Others - 2014 Global Strategic Business Report
M2 - Wed Oct 29, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrwq4b/industrial) has announced the addition of the "Industrial Enzymes - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Industrial Enzymes in US$ Thousands by the following Product Segments: - Carbohydrases - Proteases - Lipases - Others The report also analyzes the following End-Use Segments: - Food & Beverage - Detergents & Other Cleaning Products - Textiles - Animal Feed - Ethanol Production - Others The report profiles 52 companies including many key and niche players such as: - AB Enzymes GmbH - Advanced Enzyme Technologies Ltd. - Amano Enzyme Inc. - Asahi Kasei Pharma Corporation - BASF SE - BioResource International, Inc. - Chr. Hansen A/S - Codexis, Inc. - DuPont Nutrition and Health - Direvo Biotech AG - Enzymatic Deinking Technologies LLC - Hayashibara Company - Novozymes A/S - Royal DSM Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competition 3. Market Trends, Issues And Drivers 4. Product Overview 5. Product Introductions/Innovations 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. The Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 52 (including Divisions/Subsidiaries - 60) - The United States (18) - Canada (1) - Japan (3) - Europe (29) - - France (7) - - Germany (7) - - The United Kingdom (2) - - Spain (1) - - Rest of Europe (12) - Asia-Pacific (Excluding Japan) (8) - Latin America (1) For more information visit http://www.researchandmarkets.com/research/hrwq4b/industrial
CDXS: 2.45 (-0.03)

Codexis reports November 4
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 7:39AM CDT

CDXS: 2.45 (-0.03)

Codexis to Report Third Quarter 2014 Financial Results on November 4
GlobeNewswire - Tue Oct 21, 7:11AM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will report third quarter financial results after the close of market on November 4, followed at 4:30 p.m. Eastern Time by a conference call and audio webcast at www.codexis.com.
CDXS: 2.45 (-0.03)

Market Maker Surveillance Report. AHPI, APT, LAKE, IBIO, CDXS, MPO, Losing Stocks With Lowest Price Friction For Tuesday, October 14th 2014
M2 - Wed Oct 15, 3:11AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4904 companies with "abnormal" market making, 2632 companies with positive Friction Factors and 2319 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Allied Healthcare Products Inc (NASDAQ:AHPI), Alpha Pro Tech Ltd (NYSE:APT), Lakeland Industries Inc (NASDAQ:LAKE), Ibio Inc (NYSE:IBIO), Codexis Inc (NASDAQ:CDXS), Midstates Petroleum Company Inc (NYSE:MPO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
APT: 2.55 (-0.03), AHPI: 1.59 (+0.09), MPO: 1.63 (-0.05), CDXS: 2.45 (-0.03), IBIO: 0.68 (-0.04), LAKE: 8.94 (+0.07)

Codexis Appoints Biotechnology Industry Veteran, Kathleen Glaub, to Board of Directors
GlobeNewswire - Mon Sep 22, 7:07AM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Kathleen Sereda Glaub to its board of directors. Ms. Glaub's 30-year career in leadership positions with drug development and technology companies will bring strong company-building and business strategy experience to the Codexis board.
CDXS: 2.45 (-0.03)

Analyzing the Market for Cellulosic Ethanol - 2014
M2 - Wed Sep 17, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/38rww8/analyzing_the) has announced the addition of the "Analyzing the Market for Cellulosic Ethanol - 2014" report to their offering. This report is a complete handbook on this dynamic fuel source and its position in the global energy scenario. The report builds on the global energy industry and the consumption patterns which are fed by the traditional sources like Oil, Coal, Natural Gas, Nuclear Energy and Hydroelectricity. The report also presents a track on the global energy consumption patterns along with the resources being used for them. Taking into consideration the revenue cycles in the global energy markets, the report explains the revenue derived from these demand patterns from traditional sources as well as hydroelectric and wind energy. The report further also details each source individually. Taking a contrasting view point the report presents an in depth analysis of the global energy crisis and the growing recognition of unconventional energy sources for arresting this crisis. Key Topics Covered: A. Executive Summary B. Analyzing the Global Energy Industry C. Revenue Returns on Global Energy Markets D. Global Energy Demand & Supply Dynamics E. Looking at the Global Energy Crisis F. Emergence of Ethanol as an Energy Source G. Introduction to Cellulosic Ethanol H. Analyzing the Major Conversion Technologies: Producing Ethanol from Cellulosic Feedstocks I. Analyzing Ethanol Production from Different Feedstocks J. Analyzing the Utility of Ethanol in Transportation K. Commercializing Cellulosic Ethanol L. Factors Impact Growth of the Industry M. Challenges & Issues Facing the Industry N. Technological Patterns Prominent in the Industry O. Role of Industrial Biotechnology in the Development of Cellulosic Ethanol P. Production Patterns Q. Influence of Cellulosic Ethanol on the Farm Economy R. Ethanol Production and Use - Impact on the Economy S. Analyzing the Economics of Ethanol Production T. Analyzing the Regulatory Framework U. Government Incentives & Support Mechanisms V. Leading Industry Players - Abengoa Bioenergy Corporation - Archer Daniels Midland Co. - Aventine Renewable Energy Holdings - Cargill - Codexis, Inc - Dyadic International, Inc - Genencor International - Green Plains Renewable Energy. - Iogen Corporation - Lignol - Mascoma Corporation - NatureWorks, LLC - Novozymes - Pacific Ethanol, Inc. - Renova Energy (Wyoming Ethanol) - SunOpta - Tate & Lyle - The Andersons Inc. - U.S. BioEnergy Corporation - VeraSun Energy Corporation - Verenium - Xethanol BioFuels, LLC For more information visit http://www.researchandmarkets.com/research/38...lyzing_the
ADM: 53.11 (-0.06), GPRE: 25.45 (+0.16), CDXS: 2.45 (-0.03)

Global Synthetic Biology Market Forecasts and Opportunities, 2020
M2 - Tue Sep 02, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnnz65/global_synthetic) has announced the addition of the "Global Synthetic Biology Market (Products, Technologies, Applications and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. Global synthetic biology market was valued at $3.0 billion in 2013 and it is estimated to reach $38.7 billion by 2020, growing at a CAGR of 44.2% during the forecast period. Synthetic biology is a novel field that finds its origin at the intersection of biology and engineering. It involves designing and construction of biological systems or devices that can be applied in varied domains to get specified results. It's a multidisciplinary effort made by scientists to understand the functioning of biological organisms, cells & genes and implementation of artificial genetic processes to give specific characteristics to an organism. It can even be used to develop a completely new biological system. Assistance from government and private organizations, rising number of entities conducting research and declining cost of DNA sequencing and synthesizing are key driving factors of the market. Governments are providing funds to research organizations, assisting them to find novel applications of synthetic biology. Bio-safety & bio-security issues, ethical issues and regulations are key retraining factors of the market. The fact that synthetic biology can be misused has raised concerns all around the world. Further, there are possibilities of accidental release of pathogens or genetically modified organisms into free atmosphere. Report Scope Key Deliverables Market by Products - Enabling Products - DNA Synthesis - Oligonucleotide Synthesis - Enabled Products - Pharmaceuticals - Chemicals - Biofuels - Agriculture - Core Products - Synthetic DNA - Synthetic Genes - Synthetic Cells - XNA - Chassis Organisms Market by Technology - Enabling Technology - Genome Engineering - Microfluidics technologies - DNA synthesis & sequencing technologies - Bioinformatics technologies - Biological components and integrated systems technologies - Enabled Technology - Pathway engineering - Synthetic microbial consortia - Biofuels technologies Market by Application Research & Development - Chemicals - Agriculture - Pharmaceuticals & Diagnostics - Biofuels - Others (Environment, Biotechnology & Biomaterials, etc.) Companies Mentioned - Algenol Biofuels - BASF - BioAmber - BioSearch Technologies - Butamax Advanced Biofuels - Codexis Inc. - Dupont - GEN9 Inc. - Gensript Corporation - Origene Technologies - Synthetic Genomics For more information visit http://www.researchandmarkets.com/research/jn..._synthetic
CDXS: 2.45 (-0.03)

Codexis Reports Financial Results for the Second Quarter of 2014
GlobeNewswire - Wed Aug 06, 3:02PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced its financial results for the second quarter ended June 30, 2014.
CDXS: 2.45 (-0.03)

5 Stocks Ready for Breakouts
at The Street - Mon Aug 04, 9:14AM CDT
These stocks are within range of triggering breakout trades.
BLUE: 88.76 (+3.23), TSLA: 222.26 (+1.29), ZPIN: 15.46 (-0.16), OVTI: 26.47 (+0.02), CDXS: 2.45 (-0.03), ATRO: 52.37 (+1.31)

Codexis to Announce Second Quarter 2014 Financial Results on August 6, 2014
GlobeNewswire - Thu Jul 31, 3:43PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will host a live conference call and audio webcast on Wednesday, August 6, 2014 at 4:30 p.m. Eastern Time to discuss its second quarter 2014 financial results. The call and webcast will follow the release of second quarter financial results after market close. A recorded version of the call will be available approximately one hour after the call on the Investors section of the company's website, www.codexis.com, and will be archived for up to 30 days.
CDXS: 2.45 (-0.03)

Gordon Sangster to Join Codexis as Senior Vice President & Chief Financial Officer
GlobeNewswire - Mon Jul 28, 3:01PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that Gordon Sangster has agreed to join Codexis as Senior Vice President & Chief Financial Officer. Gordon, who will start on August 18, 2014, will manage all aspects of Codexis' financial and accounting functions and will report to John Nicols, President & Chief Executive Officer.
CDXS: 2.45 (-0.03)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 126

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 117

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 156

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 94

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

NewRiver REIT Announces Scrip Dividend Reference Price

Updated Category News Views 335

NewRiver REIT's Scrip Dividend Reference Price Announcement NewRiver REIT plc has made a significant announcement regarding the reference price for its scrip dividend option, which is tied to its interim dividend. This dividend pertains to the six-month period ending on September 30, 2024. Understanding the Scrip Dividend Option The reference price has been set at 73.41...

Continue Reading
Upcoming Shareholders' Meeting Announcement for Siguldas CMAS

Updated Category News Views 200

Important Shareholders' Meeting Information The Management Board of Joint Stock Company ‘Siguldas ciltslietu un m?ksl?g?s aps?klošanas stacija’ is excited to announce an important shareholders' meeting for the company. This meeting is a key opportunity for all shareholders to engage in discussions concerning the company's future. Meeting Details Scheduled for April...

Continue Reading
Empowering Women in Finance: Insights from Cboe Leaders

Updated Category News Views 168

Empowering Women in Finance In a recent dialogue, Cathy Clay, Executive Vice President and Global Head of Derivatives at Cboe, along with Meghan Dugan, Senior Vice President overseeing U.S. Options, and Alexandra Szakats, Vice President and Head of The Options Institute, shared their journeys and advice regarding their roles as leaders in the options industry. These women...

Continue Reading
Bird Dog Whiskey Debuts Premium Kentucky Straight Bourbon

Updated Category News Views 220

Bird Dog Whiskey Unveils Select Reserve Kentucky Straight Bourbon Bird Dog Whiskey has exciting news for bourbon enthusiasts. The brand has launched a highly anticipated addition to its lineup: the Select Reserve Kentucky Straight Bourbon Whiskey. This new offering is set to capture the hearts of loyal fans. A Smooth and Rich Bourbon Experience At 86 proof, Bird Dog...

Continue Reading
Vera Therapeutics Announced Key Stock Option Grants for New Hires

Updated Category News Views 160

Introduction to Vera Therapeutics' Inducement Awards Vera Therapeutics, Inc. (Nasdaq: VERA) has proudly announced a significant step in its commitment to fostering talent by granting inducement awards to new employees. On a recent date, the Compensation Committee approved these awards, which included stock options and restricted stock units (RSUs) to reward and attract...

Continue Reading